Aspergillosis in bone marrow transplant recipients.
Invasive aspergillosis in bone marrow transplant recipient is associated with a high mortality. Diagnosis is often delayed because the inflammatory response is blunted by immunosuppression. The gold standard of tissue biopsy is often considered too in invasive as the procedure is often complicated by bleeding and secondary infection. Recent finding on non-invasive tests such as serial measurement of peripheral blood galactomannan antigen or DNA appears to be promising. However, the limited availability of such tests and requirement for expertise are still hampering their use in routine clinical management. More often than not, initiation of antifungal therapy is empirical and based on suggestive radiological changes. Amphotericin B remains the gold standard of therapy but liposconal preparation may prove to be less nephrotoxic and equally effective. Treatment outcome depends more on the acceleration of the recovery of the immune system and the reduction of anti-GVHD therapy than the antifungal agent followed by surgical resection. The efficacy of many reported anti-aspergillosis prophylactic regimen has not been proved in randomized control trials. Despite the absence of data, such policy should still be considered in transplant units with high incidence of aspergillus or undergoing renovation.
Ho
P L
PL
Division of Infectious Diseases, Department of Microbiology, Queen Mary Hospital, University of Hong Kong, Pokfulam Road, Pokfulum, Hong Kong.
Yuen
K Y
KY
D000391:Air Microbiology; D000935:Antifungal Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D018562:Disease Transmission, Infectious; D006801:Humans; D011379:Prognosis
D000935:Antifungal Agents